Back to Authors

Ning, Xiaoping

0009-0002-2900-6900

A5109301892 | I4210139373

Mayo Clinic

Teva Pharmaceuticals (United States)

Citations 4

Efficacy Of Fremanezumab in Patients With Chronic Migraine With or Without Concomitant Use of Preventive Medication (P4.099)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p4.099

Impact of Fremanezumab on Headache-related Disability in Patients With Migraine and Documented Inadequate Response to 2–4 Classes of Migraine Preventive Medication Classes in the Open–label Extension of the Phase 3b FOCUS Study (4416)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.4416

Efficacy and Disability Outcomes of Fremanezumab in Patients With Prior OnabotulinumtoxinA Treatment Failure: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies (P3-2.004)

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.2935

Long-term safety, tolerability, and efficacy of fremanezumab in migraine

Neurology | September 11, 2020 | Volume: 95 | Issue: 18 | Pages: No page available

10.1212/wnl.0000000000010600 | PMID 32913018